Longwood Capital Partners »

Arrivent Biopharma shares owned by Longwood Capital Partners

Quarter-by-quarter ownership of Arrivent Biopharma (AVBP) shares owned by Longwood Capital Partners from 13F filings

Historical chart of Longwood Capital Partners investment in Arrivent Biopharma

Tip: Access up to 7 years of quarterly data

All positions including Arrivent Biopharma held by Longwood Capital Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Arrivent Biopharma by Longwood Capital Partners

Quarter filed Position value Share count Share price at filing
2026-06-30 $7.6M 219k 34.74

More positions owned by Longwood Capital Partners

Praxis Precision Medicines I Com New (PRAX)
Aadi Bioscience (WHWK)
Tango Therapeutics (TNGX)
Sutro Biopharma (STRO)
Arrivent Biopharma (AVBP)
4d Molecular Therapeutics In (FDMT)
Bright Minds Biosciences Com New (DRUG)
Ocular Therapeutix (OCUL)
Erasca (ERAS)
Surrozen Com New (SRZN)
Argen Se - Sponsored Adr (ARGX)
Moonlake Immunotherapeutics Class Ord A (MLTX)
Design Therapeutics (DSGN)
Minerva Neurosciences Com New (NERV)
Taysha Gene Therapies Com Shs (TSHA)

View all positions for Longwood Capital Partners

Top funds holding Arrivent Biopharma

Suvretta Capital Management
Infinitum Asset Management
Hillhouse Capital Advisors
BlackRock
OrbiMed Advisors
FMR
Octagon Capital Advisors
Vanguard Capital Management
Sofinnova Ventures
Vivo Capital
Novo A/S
General Catalyst Group Management
State Street Corporation
Logos Global Management
Geode Capital Management

View all funds holding Arrivent Biopharma